secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001104659-25-056160
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet partner Ascletis reports positive Phase 3 acne results for denifanstat; Sagimet starts Phase 1 of TVB-3567
--------------------------------------------------------------------------------

- Denifanstat (50mg once daily) met all primary and secondary endpoints vs placebo in Phase 3 acne trial (n=480) in China.
- Treatment success (IGA) 33.2% denifanstat vs 14.6% placebo (p<0.0001); total lesion count change −57.4% vs −35.4%.
- Denifanstat well-tolerated; TEAEs comparable to placebo, only dry skin (6.3%) and dry eye (5.9%) above 5%.
- Ascletis plans to submit denifanstat for approval to China's NMPA; Sagimet initiated Phase 1 of TVB-3567 for US acne.
- Oral FASN inhibition offers novel mechanism for moderate-to-severe acne, a condition affecting 640M+ globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925056160/0001104659-25-056160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925056160/tm2517101d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-056160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer